Geographic patterns of carbapenem-resistant, multi-drug-resistant and difficult-to-treat Acinetobacter baumannii in the Asia-Pacific region: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020

替加环素 鲍曼不动杆菌 肉汤微量稀释 粘菌素 美罗培南 抗菌剂 抗药性 头孢菌素 微生物学 抗生素 医学 抗生素耐药性 生物 最小抑制浓度 细菌 铜绿假单胞菌 遗传学
作者
Chih-Hao Chen,Pin-Han Wu,Min‐Chi Lu,Mao‐Wang Ho,Po‐Ren Hsueh
出处
期刊:International Journal of Antimicrobial Agents [Elsevier BV]
卷期号:61 (2): 106707-106707 被引量:18
标识
DOI:10.1016/j.ijantimicag.2022.106707
摘要

This study evaluated the in-vitro activity of multiple classes of antibiotics, including novel β-lactam combination agents, tigecycline and colistin, against carbapenem-resistant (CRAB), multi-drug-resistant (MDRAB) and difficult-to-treat (DTRAB) Acinetobacter baumannii. Minimum inhibitory concentrations (MICs) were determined using the broth microdilution method. Susceptibility profiles and the distribution of selected antimicrobials among countries were illustrated and examined based on the breakpoints of the Clinical and Laboratory Standards Institute, European Committee on Antimicrobial Susceptibility Testing and the US Food and Drug Administration. In total, 847 A. baumannii isolates were evaluated, and 692 isolates were characterized as CRAB, MDRAB or DTRAB. The prevalence of drug-resistant A. baumannii was >70.0% in South Korea, India and China, while the resistance rate of tigecycline was <5.5%. The MICs of meropenem and meropenem/vaborbactam for drug-resistant A. baumannii were equal (both MIC50 and MIC90 were 32 mg/L, range 0.25-32 mg/L). The overall resistance rate remained high for multiple classes of antibiotics, including penicillins, cephalosporins, carbapenems, quinolones and aminoglycosides (>84.0%, >96.0%, >98.0%, >88.0% and >87.0%, respectively), but not colistin or tigecycline (1.1% and 4.3%, respectively). China showed the lowest susceptibility to tigecycline for drug-resistant A. baumannii isolates compared with other countries. In conclusion, the resistance rate of drug-resistant A. baumannii remains high against multiple classes of antimicrobials. Colistin was the most potent agent, followed by tigecycline. The geographic pattern of tigecycline-resistant A. baumannii varied among countries. Therefore, continuous surveillance of A. baumannii resistance profiles in different regions is required.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
FashionBoy的应助被djbj2022采纳,获得10
1秒前
十三发布了新的文献求助10
2秒前
无花果的应助被你爱吃鱼吗采纳,获得10
2秒前
璨璨完成签到,获得积分10
2秒前
3秒前
wpz发布了新的文献求助10
3秒前
公西钧发布了新的文献求助10
4秒前
Sherlock完成签到,获得积分10
4秒前
田様的应助被无辜的皮卡丘采纳,获得10
5秒前
Euler发布了新的文献求助10
6秒前
李健的应助被冬天该很好采纳,获得10
6秒前
6秒前
科研通AI6.2的应助被prisms采纳,获得10
7秒前
7秒前
今后的应助被璨璨采纳,获得10
8秒前
zzww发布了新的文献求助10
8秒前
9秒前
刘mt完成签到 ,获得积分10
9秒前
9秒前
IU秋阳发布了新的文献求助10
10秒前
大胆芒果完成签到,获得积分10
10秒前
10秒前
科研通AI2S的应助被wuqs采纳,获得10
11秒前
12秒前
海林涵完成签到,获得积分10
12秒前
Sano发布了新的文献求助10
13秒前
14秒前
djbj2022发布了新的文献求助10
14秒前
Pioneer完成签到 ,获得积分10
15秒前
IDHNAPHO发布了新的文献求助10
15秒前
小新小新发布了新的文献求助10
16秒前
16秒前
着急的天菱完成签到,获得积分10
16秒前
16秒前
独孤辰发布了新的文献求助10
16秒前
XDMae完成签到,获得积分10
17秒前
xzy发布了新的文献求助10
18秒前
sunny完成签到,获得积分10
19秒前
科研通AI6.4的应助被tcwei采纳,获得10
20秒前
xxx发布了新的文献求助10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
IRTSD: Open-Source Data and Toolset for Electromagnetic Transient Analysis of Disturbances and IBR Control Malfunctions in Transmission Systems 1000
Spec 401: Standards for Jet Fuel Facility and Equipment Commissioning and Flushing at Airports, 2026.1 (Original Issue) 1000
Spec 103: Standard for Jet Fuel Quality Control at Airports, Revision 2026.1 1000
A Consideration on Use of Material Grades for Hull Structural Members Based on Fracture Toughness(Second Report) 500
AI Disclosure in Annual Reports: Evolution, Determinants, and Capital Market Participants’ Perceptions 500
5th World Conference on Detergents: Reinventing the Industry : Opportunities and Challenges 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8107023
求助须知:如何正确求助?哪些是违规求助? 9515315
关于积分的说明 21497426
捐赠科研通 7683172
什么是DOI,文献DOI怎么找? 3410223
关于科研通互助平台的介绍 2537685
邀请新用户注册赠送积分活动 2450127